LadRx Past Earnings Performance
Past criteria checks 0/6
LadRx has been growing earnings at an average annual rate of 23%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
23.0%
Earnings growth rate
27.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How LadRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -3 | 3 | 1 |
| 30 Jun 24 | 0 | -3 | 3 | 1 |
| 31 Mar 24 | 0 | 2 | 3 | 0 |
| 31 Dec 23 | 0 | 0 | 4 | 0 |
| 30 Sep 23 | 0 | 0 | 7 | 0 |
| 30 Jun 23 | 0 | 0 | 4 | 0 |
| 31 Mar 23 | 0 | -4 | 4 | 0 |
| 31 Dec 22 | 0 | -5 | 5 | 0 |
| 30 Sep 22 | 0 | -13 | 2 | 0 |
| 30 Jun 22 | 0 | -13 | 6 | 0 |
| 31 Mar 22 | 0 | -14 | 6 | 0 |
| 31 Dec 21 | 0 | -13 | 6 | 0 |
| 30 Sep 21 | 0 | -6 | 5 | 0 |
| 30 Jun 21 | 0 | -7 | 6 | 1 |
| 31 Mar 21 | 0 | -7 | 6 | 1 |
| 31 Dec 20 | 0 | -7 | 6 | 1 |
| 30 Sep 20 | 0 | -8 | 7 | 1 |
| 30 Jun 20 | 0 | -7 | 7 | 0 |
| 31 Mar 20 | 0 | -7 | 7 | 0 |
| 31 Dec 19 | 0 | -8 | 7 | 0 |
| 30 Sep 19 | 0 | -6 | 6 | 0 |
| 30 Jun 19 | 0 | -7 | 7 | 0 |
| 31 Mar 19 | 0 | -7 | 7 | 0 |
| 31 Dec 18 | 0 | -9 | 8 | 0 |
| 30 Sep 18 | 0 | -8 | 9 | -1 |
| 30 Jun 18 | 0 | -10 | 11 | 4 |
| 31 Mar 18 | 0 | -23 | 12 | 10 |
| 31 Dec 17 | 0 | -30 | 13 | 16 |
| 30 Sep 17 | 0 | -38 | 15 | 24 |
| 30 Jun 17 | 0 | -45 | 14 | 28 |
| 31 Mar 17 | 0 | -49 | 15 | 35 |
| 31 Dec 16 | 0 | -51 | 16 | 36 |
| 30 Sep 16 | 0 | -65 | 16 | 42 |
| 30 Jun 16 | 0 | -60 | 15 | 41 |
| 31 Mar 16 | 0 | -54 | 15 | 39 |
| 31 Dec 15 | 0 | -59 | 14 | 43 |
| 30 Sep 15 | 0 | -50 | 14 | 40 |
| 30 Jun 15 | 0 | -48 | 14 | 42 |
| 31 Mar 15 | 0 | -52 | 13 | 42 |
| 31 Dec 14 | 0 | -30 | 13 | 37 |
| 30 Sep 14 | 0 | -44 | 13 | 34 |
| 30 Jun 14 | 0 | -48 | 13 | 27 |
| 31 Mar 14 | 0 | -36 | 12 | 21 |
| 31 Dec 13 | 0 | -47 | 10 | 18 |
Quality Earnings: LADX is currently unprofitable.
Growing Profit Margin: LADX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LADX is unprofitable, but has reduced losses over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare LADX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LADX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LADX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.